Baseline demographics and clinical characteristics of the patients with Marfan syndrome in the RESVcue study and COMPARE trial group
| RESVcue n=57 | COMPARE n=101 | |
| General features | ||
| Age at inclusion (years) | 37±9 | 38±12 |
| Sex (male) | 28 (49%) | 59 (58%) |
| Body surface area (m2) | 2.11±0.3 | 2.02±0.2* |
| FBN1 mutation | ||
| Dominant-negative | 25 (44%) | 47 (46%)* |
| Haploin sufficient | 26 (46%) | 27 (26.7%)* |
| Unknown effect | 6 (10%) | 27 (26.7%)* |
| Cardiac medication | 44 (72%) | 101 (100%)* |
| β-blocker | 33 (58%) | 74 (73%) |
| Losartan | 37 (71%) | 101 (100%)* |
| β-blocker and losartan | 25 (44%) | 74 (73%)* |
| History of aortic root surgery | 26 (46%) | 31 (31%) |
| Bicuspid aortic valve | 0 (0%) | 1 (1%) |
| Systolic BP (mm Hg) | 116±13 | 124±13* |
| Diastolic BP (mm Hg) | 67±10 | 74±11* |
| Days between baseline and follow-up (range) | 423 (283–752) | 1150 (669–1631) |
| Days between pre-trial and inclusion (range) | 1186 (371–3107) | NA |
*P value <0.05 comparing RESVcue study participants and the COMPARE trial participants.
NA, not applicable.